Why FDA Review Delays Won’t Be Fixed by Leadership Turnover Alone

Calls for personnel change at FDA often carry the implication that a new leader can reset the agency’s performance almost overnight. But device review delays are usually the product of structural factors: staffing constraints, increasingly complex submissions, and the growing need for specialized expertise across software, AI, cybersecurity, and clinical evidence generation.

That reality matters because the old model of device review assumed a relatively stable product with a bounded technical profile. Today’s products are often iterative, connected, and dependent on postmarket monitoring. A reviewer is no longer evaluating a static artifact; they are evaluating a system that may change after clearance and may behave differently across settings and patient groups.

Leadership can certainly influence tone, priorities, and internal coordination. But unless the agency has the tools and capacity to manage more sophisticated products, review times will remain constrained. In that sense, turnover may change the optics, but it does not remove the underlying demand on the agency’s scientific and regulatory infrastructure.

For industry, the lesson is to stop assuming that delays are merely political friction. They are also a signal that FDA needs better submission quality, clearer evidentiary standards, and perhaps more explicit pathways for digital and AI-enabled devices. Without those changes, the system will keep treating symptoms rather than resolving the cause.